文献速递胃肠动力与功能性疾病

肠易激综合征药物治疗的安全性:系统评价与荟萃分析

The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Gastroenterol · 2025-06-05

该系统评价与荟萃分析检索截至2024年10月的PubMed、Web of Science和Cochrane数据库,纳入54项报告因不良事件停药率的肠易激综合征药物治疗临床试验,采用随机效应模型合并数据,主要结局为需伤害人数(NNH)。结果显示,三环类药物(尤其高剂量)、替纳帕诺和阿洛司琼因不良事件停药的绝对风险最高,利福昔明为研究中安全性最高的药物。

要点

  • 便秘型肠易激综合征药物中,替纳帕诺的NNH为16(P<0.01),利那洛肽为35(P<0.01)。
  • 腹泻型肠易激综合征药物中,阿洛司琼的NNH为14(P<0.01),艾沙度林为32(P<0.01)。
  • 三环类药物的NNH为24(P<0.01),多数不良事件为一过性且无长期后遗症。

核心结论

  • 在肠易激综合征药物中,三环类药物(尤其高剂量)、替纳帕诺和阿洛司琼因不良事件停药的绝对风险最高,利福昔明为研究中安全性最高的药物。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、Web of Science和Cochrane数据库截至2024年10月,纳入54项报告因不良事件停药率的肠易激综合征药物治疗临床试验,采用随机效应模型合并数据。

主要发现

  • 便秘型肠易激综合征药物中,利那洛肽的NNH为35(P<0.01),鲁比前列酮为53(P=0.59),普卡那肽为59(P<0.01),替加色罗为58(P=0.03),替纳帕诺为16(P<0.01)。
  • 腹泻型肠易激综合征药物中,阿洛司琼的NNH为14(P<0.01),艾沙度林为32(P<0.01),利福昔明和拉莫司琼的NNH均为负值但无统计学显著性。
  • 肠易激综合征全局症状药物中,三环类药物的NNH为24(P<0.01)。
  • 许多不良事件为一过性且无长期后遗症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Understanding the safety of pharmacotherapy for irritable bowel syndrome (IBS) enables individuals to make informed treatment decisions. While many studies include the number needed to treat to highlight therapeutic benefits, adding the number needed to harm (NNH), a measure we evaluate herein, could enable more comprehensive risk-benefit assessments. METHODS: PubMed, Web of Science, and Cochrane databases were searched through October 2024. Clinical trials investigating IBS pharmacotherapies including discontinuation rates because of adverse events (AEs) were included. Data were pooled using a random-effects model. The primary outcome was NNH for each pharmacotherapy, defined as the reciprocal of the absolute difference in risk of AEs leading to treatment discontinuation between the experimental and placebo groups. Secondary outcomes included the relative risk of withdrawing because of an AE and the most common AEs for each drug. RESULTS: Fifty-four trials met inclusion criteria. For constipation-predominant IBS pharmacotherapies, the NNH for linaclotide, lubiprostone, plecanatide, tegaserod, and tenapanor was 35 ( P < 0.01), 53 ( P = 0.59), 59 ( P < 0.01), 58 ( P = 0.03), and 16 ( P < 0.01), respectively. For diarrhea-predominant IBS pharmacotherapies, the NNH for alosetron and eluxadoline was 14 ( P < 0.01) and 32 ( P < 0.01) whereas the NNH for both rifaximin and ramosetron was a negative, although statistically insignificant, value. For IBS global symptom pharmacotherapies, the tricyclics, the NNH was 24 ( P < 0.01). Many AEs were transient without long-term sequela. DISCUSSION: Among pharmacotherapies for IBS, tricyclics (especially at elevated doses), tenapanor, and alosetron have the highest absolute risk of discontinuation because of an AE when compared with rifaximin, the safest pharmacotherapy studied.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Busam JA, Batta N, Shah ED, et al. The Safety of Pharmacotherapy for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2025. PMID: 40471839. doi:10.14309/ajg.0000000000003572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。